Pediatric pityriasis lichenoides and cutaneous T-cell lymphoma

Current Opinion in Pediatrics

Volumn 19, Issue 4, 2007, Pages 441-445

  Lam, Joseph ^a   Pope, Elena ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Cutaneous T cell lymphoma; Papulosquamous; Parapsoriasis; Pityriasis lichenoides

Indexed keywords

ALPHA INTERFERON; ANTIHISTAMINIC AGENT; BEXAROTENE; CALCINEURIN INHIBITOR; CARMUSTINE; CHLORMETHINE; CORTICOSTEROID; CYCLOSPORIN; ERYTHROMYCIN; IMIQUIMOD; METHOTREXATE; PSORALEN; RETINOID; STEROID; TAZAROTENE;

ACUTE DISEASE; CANCER CHEMOTHERAPY; CHICKENPOX; CHILDHOOD CANCER; CHRONIC DISEASE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CUTANEOUS T CELL LYMPHOMA; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE DURATION; ELECTRON THERAPY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMPETIGO; LIFE EXPECTANCY; LONG TERM CARE; LOW DRUG DOSE; OCCUPATIONAL EXPOSURE; PAPULOSIS; PATHOGENESIS; PHOTOTHERAPY; PITYRIASIS LICHENOIDES; PITYRIASIS ROSEA; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; PUVA; REMISSION; REVIEW; SCABIES; SKIN BIOPSY; SYSTEMIC THERAPY; TOPICAL TREATMENT; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

ACUTE DISEASE; CHILD; CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; PITYRIASIS LICHENOIDES; SKIN NEOPLASMS;

EID: 34447524952     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e328224b7c3     Document Type: Review

References (54)

1. Ersoy-Evans S, Greco MF, Mancini AJ, et al. Pityriasis lichenoides in childhood: a retrospective review of 124 patients. J Am Acad Dermatol 2007; 56:205-210. The largest review of pediatric pityriasis lichenoides in the literature. An excellent summary of the disease and clinical characteristics.
2. Gelmetti C, Rigoni C, Alessi E, et al. Pityriasis lichenoides in children: a longterm follow-up of eighty-nine cases. J Am Acad Dermatol 1990; 23 (3 Pt 1):473-478.
3. Romani J, Puig L, Fernandez-Figueras MT, et al. Pityriasis lichenoides in children: clinicopathologic review of 22 patients. Pediatr Dermatol 1998; 15:1-6.
4. Clayton R, Haffenden G. An immunofluorescence study of pityriasis lichenoides. Br J Dermatol 1978; 99:491-493.
5. Clayton R, Haffenden G, Du Vivier A, et al. Pityriasis lichenoides: an immune complex disease. Br J Dermatol 1977; 97:629-633.
6. Magro C, Crowson AN, Kovatich A, Burns F. Pityriasis lichenoides: a clonal T-cell lymphoproliferative disorder. Hum Pathol 2002; 33:788-795.
7. Tomasini D, Tomasini CF, Cerri A, et al. Pityriasis lichenoides: a cytotoxic T-cell-mediated skin disorder: evidence of human parvovirus B19 DNA in nine cases. J Cutan Pathol 2004; 31:531-538.
8. Tsai KS, Hsieh HJ, Chow KC, et al. Detection of cytomegalovirus infection in a patient with febrile ulceronecrotic Mucha-Habermann's disease. Int J Dermatol 2001; 40:694-698.
9. Bowers S, Warshaw EM. Pityriasis lichenoides and its subtypes. J Am Acad Dermatol 2006; 55:557-572. A good and comprehensive review of PLEVA, PLC and febrile ulceronecrotic Mucha-Habermann's disease.
10. Tsuji T, Kasamatsu M, Yokota M, et al. Mucha-Habermann disease and its febrile ulceronecrotic variant. Cutis 1996; 58:123-131.
11. Ko JW, Seong JY, Suh KS, et al. Pityriasis lichenoides-like mycosis fungoides in children. Br J Dermatol 2000; 142:347-352.
12. Child FJ, Fraser-Andrews EA, Russell-Jones R. Cutaneous T-cell lymphoma presenting with 'segmental pityriasis lichenoides chronica'. Clin Exp Dermatol 1998; 23:232.
13. Simon D, Boudny C, Nievergelt H, et al. Successful treatment of pityriasis lichenoides with topical tacrolimus. Br J Dermatol 2004; 150:1033-1035.
14. Mallipeddi R, Evans AV. Refractory pityriasis lichenoides chronica successfully treated with topical tacrolimus. Clin Exp Dermatol 2003; 28:456-458.
15. Truhan AP, Hebert AA, Esterly NB. Pityriasis lichenoides in children: therapeutic response to erythromycin. J Am Acad Dermatol 1986; 15:66-67.
16. Piamphongsant T. Tetracycline for the treatment of pityriasis lichenoides. Br J Dermatol 1974; 91:319-322.
17. Shelley WB, Griffith RF. Pityriasis lichenoides et varioliformis acuta: a report of a case controlled by a high dose of tetracycline. Arch Dermatol 1969; 100:596-597.
18. Pavlotsky F, Baum S, Barzilai A, et al. UVB therapy of pityriasis lichenoides: our experience with 29 patients. J Eur Acad Dermatol Venereol 2006; 20:542-547.
19. Lynch PJ, Saied NK. Methotrexate treatment of pityriasis lichenoides and lymphomatoid papulosis. Cutis 1979; 23:634-636.
20. Herron MD, Bohnsack JF, Vanderhooft SL. Septic, CD-30 positive febrile ulceronecrotic pityriasis lichenoides et varioliformis acuta. Pediatr Dermatol 2005; 22:360-365.
21. Tsianakas A, Hoeger PH. Transition of pityriasis lichenoides et varioliformis acuta to febrile ulceronecrotic Mucha-Habermann disease is associated with elevated serum tumour necrosis factor-alpha. Br J Dermatol 2005; 152:794-799.
22. Tomasini D, Zampatti C, Palmedo G, et al. Cytotoxic mycosis fungoides evolving from pityriasis lichenoides chronica in a seventeen-year-old girl: report of a case. Dermatology 2002; 205:176-179.
23. Thomson KF, Whittaker SJ, Russell-Jones R, et al. Childhood cutaneous T-cell lymphoma in association with pityriasis lichenoides chronica. Br J Dermatol 1999; 141:1146-1148.
24. Kadin ME. T-cell clonality in pityriasis lichenoides: evidence for a premalignant or reactive immune disorder? Arch Dermatol 2002; 138:1089-1099.
25. Shieh S, Mikkola DL, Wood GS. Differentiation and clonality of lesional lymphocytes in pityriasis lichenoides chronica. Arch Dermatol 2001; 137:305-308.
26. Weinstock MA, Horm JW. Mycosis fungoides in the United States: increasing incidence and descriptive epidemiology. JAMA 1988; 260:42-46.
27. Weinstock MA, Reynes JF. The changing survival of patients with mycosis fungoides: a population-based assessment of trends in the United States. Cancer 1999; 85:208-211.
28. Weinstock MA, Gardstein B. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Am J Public Health 1999; 89:1240-1244.
29. Slater D. The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants. Br J Dermatol 2005; 153:874-880.
30. Zackheim HS, McCalmont TH. Mycosis fungoides: the great imitator. J Am Acad Dermatol 2002; 47:914-918.
31. Zackheim HS. Treatment of mycosis fungoides/Sezary syndrome: the University of California, San Francisco (UCSF) approach. Int J Dermatol 2003; 42:53-56.
32. Pimpinelli N, Olsen EA, Santucci M, et al. International Society for Cutaneous Lymphoma. J Am Acad Dermatol 2005; 53:1053-1063.
33. Bunn PA Jr, Lamberg SI. Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep 1979; 63:725-728.
34. Abha G, Lam J, Weitzman S, et al. Cutaneous T-cell lymphoma (CTCL) in children: report from an international registry [abstract]. Pediatr Blood Cancer 2006; 46:846.
35. Ben-Amitai D, Michael D, Feinmesser M, et al. Juvenile mycosis fungoides diagnosed before 18 years of age. Acta Derm Venereol 2003; 83:451-456.
36. Wain EM, Orchard GE, Whittaker SJ, et al. Outcome in 34 patients with juvenile-onset mycosis fungoides: a clinical, immunophenotypic, and molecular study. Cancer 2003; 98:2282-2290.
37. Fink-Puches R, Chott A, Ardigo M, et al. The spectrum of cutaneous lymphomas in patients less than 20 years of age. Pediatr Dermatol 2004; 21:525-533.
38. Tan E, Tay YK, Giam YC. Profile and outcome of childhood mycosis fungoides in Singapore. Pediatr Dermatol 2000; 17:352-356.
39. Quaglino P, Zaccagna A, Verrone A, et al. Mycosis fungoides in patients under 20 years of age: report of 7 cases, review of the literature and study of the clinical course. Dermatology 1999; 199:8-14.
40. Neuhaus IM, Ramos-Caro FA, Hassanein AM. Hypopigmented mycosis fungoides in childhood and adolescence. Pediatr Dermatol 2000; 17:403-406.
41. Lambroza E, Cohen SR, Phelps R, et al. Hypopigmented variant of mycosis fungoides: demography, histopathology, and treatment of seven cases. J Am Acad Dermatol 1995; 32:987-993.
42. Wood GS, Hong SR, Sasaki DT, et al. Leu-8/CD7 antigen expression by CD3+ T cells: comparative analysis of skin and blood in mycosis fungoides/Sezary syndrome relative to normal blood values. J Am Acad Dermatol 1990; 22:602-607.
43. Michie SA, Abel EA, Hoppe RT, et al. Discordant expression of antigens between intraepidermal and intradermal T cells in mycosis fungoides. Am J Pathol 1990; 137:1447-1451.
44. Naraghi ZS, Seirafi H, Valikhani M, et al. Assessment of histologic criteria in the diagnosis of mycosis fungoides. Int J Dermatol 2003; 42:45-52.
45. Santucci M, Biggeri A, Feller AC, et al. Accuracy, concordance, and reproducibility of histologic diagnosis in cutaneous T-cell lymphoma: an EORTC Cutaneous Lymphoma Project Group Study. European Organization for Research and Treatment of Cancer. Arch Dermatol 2000; 136:497-502.
46. Whittaker SJ, Marsden JR, Spittle M, et al. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 2003; 149:1095-1107.
47. Fung MA, Murphy MJ, Hoss DM, et al. Practical evaluation and management of cutaneous lymphoma. J Am Acad Dermatol 2002; 46:325-357.
48. Ramsay DL, Meller JA, Zackheim HS. Topical treatment of early cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995; 9:1031-1056.
49. Zackheim HS. Topical carmustine (BCNU) for patch/plaque mycosis fungoides. Semin Dermatol 1994; 13:202-206.
50. Zackheim HS. Cutaneous T cell lymphoma: update of treatment. Dermatology 1999; 199:102-105.
51. Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Arch Dermatol 1998; 134:949-954.
52. de Quatrebarbes J, Esteve E, Bagot M, et al. Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study. Arch Dermatol 2005; 141:1117-1122.
53. Deeths MJ, Chapman JT, Dellavalle RP, et al. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol 2005; 52:275-280.
54. Apisarnthanarax N, Talpur R, Ward S, et al. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study. J Am Acad Dermatol 2004; 50:600-607.